Jack L. Wyszomierski Sells 15,300 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL – Get Rating) Director Jack L. Wyszomierski sold 15,300 shares of Exelixis stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $16.61, for a total value of $254,133.00. Following the completion of the transaction, the director now directly owns 317,467 shares of the company’s stock, valued at approximately $5,273,126.87. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Exelixis Trading Up 3.9 %

Shares of NASDAQ:EXEL opened at $17.47 on Wednesday. The stock has a 50 day moving average of $17.13 and a 200 day moving average of $16.75. The company has a market cap of $5.66 billion, a PE ratio of 30.65, a price-to-earnings-growth ratio of 0.67 and a beta of 0.69. Exelixis, Inc. has a 12-month low of $14.87 and a 12-month high of $23.40.

Exelixis (NASDAQ:EXEL – Get Rating) last posted its quarterly earnings results on Tuesday, February 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). Exelixis had a return on equity of 7.54% and a net margin of 11.31%. The business had revenue of $423.92 million during the quarter, compared to the consensus estimate of $418.71 million. During the same quarter in the previous year, the company earned $0.29 earnings per share. The company’s revenue for the quarter was down 6.0% compared to the same quarter last year. Equities research analysts predict that Exelixis, Inc. will post 0.67 earnings per share for the current fiscal year.

Institutional Trading of Exelixis

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of Exelixis by 1.0% during the 3rd quarter. BlackRock Inc. now owns 33,895,320 shares of the biotechnology company’s stock worth $531,477,000 after acquiring an additional 338,589 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Exelixis by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 31,284,832 shares of the biotechnology company’s stock worth $490,546,000 after acquiring an additional 220,099 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Exelixis by 5.5% during the 2nd quarter. Renaissance Technologies LLC now owns 17,783,937 shares of the biotechnology company’s stock worth $370,262,000 after acquiring an additional 921,659 shares in the last quarter. FMR LLC raised its holdings in Exelixis by 1.1% during the 2nd quarter. FMR LLC now owns 17,397,286 shares of the biotechnology company’s stock valued at $362,212,000 after buying an additional 197,254 shares during the period. Finally, State Street Corp raised its holdings in Exelixis by 3.4% during the 3rd quarter. State Street Corp now owns 13,019,900 shares of the biotechnology company’s stock valued at $204,152,000 after buying an additional 423,520 shares during the period. 84.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EXEL has been the subject of a number of recent analyst reports. Truist Financial decreased their target price on Exelixis from $35.00 to $32.00 in a research report on Friday, December 9th. Cowen decreased their target price on Exelixis from $21.00 to $20.00 in a research report on Monday, January 9th. Wells Fargo & Company initiated coverage on Exelixis in a research report on Thursday, March 9th. They issued an “overweight” rating and a $23.00 target price for the company. JMP Securities decreased their target price on Exelixis from $25.00 to $24.00 and set a “market outperform” rating for the company in a research report on Thursday, January 19th. Finally, Piper Sandler reissued an “overweight” rating and issued a $32.00 target price on shares of Exelixis in a research report on Wednesday, February 8th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.00.

About Exelixis

(Get Rating)

Exelixis, Inc operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.